🔎 Trials Near Me

Home › Idiopathic Thrombocytopenic Purpura › Massachusetts

Pag-aaral pangklinika para sa Idiopathic Thrombocytopenic Purpura sa Massachusetts

6 pag-aaral para sa Idiopathic Thrombocytopenic Purpura ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06722235

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

  • Beth Israel Deaconess Medical Center, Boston
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07095127

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

  • Beth Israel Deaconess Medical Center, Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT07104565

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
  • University of Massachusetts Chan Medical School, Worcester
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06948318

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

  • Massachusetts General Hospital Cancer Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Mass General Brigham Cancer Institute, Danvers
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT07007962

Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia

  • Massachusetts General Hospital, Boston
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 10, 2025 · NCT06817395

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.